Heron Therapeutics, Inc. (HRTX)
| Market Cap | 847.59M |
| Revenue (ttm) | 86.30M |
| Net Income (ttm) | -228.32M |
| Shares Out | 101.94M |
| EPS (ttm) | -2.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,053,403 |
| Open | 8.48 |
| Previous Close | 8.70 |
| Day's Range | 8.18 - 8.67 |
| 52-Week Range | 8.09 - 20.45 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 31.50 (+278.8%) |
| Earnings Date | Nov 3, 2021 |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 31.50, which is an increase of 278.83% from the latest price.
News
Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion
The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.
Why Heron Therapeutics Shares Rose Nearly 15% This Week
The company got approval for an expanded use for its post-surgery pain therapy.
FDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med
The FDA has approved Heron Therapeutics Inc's (NASDAQ: HRTX) supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication. Zynrelef is now indica...
2 Short-Squeeze Candidates That Could Go Parabolic Soon
Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...
Heron Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights ...
SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
These once-promising biotech stocks are trading at a fraction of their all-time highs right now.
Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Ind...
SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme...
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent...
SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNR...
SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...
Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients
Heron Therapeutics Inc (NASDAQ: HRTX) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 6...
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients...
SAN DIEGO, July 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...
Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative...
SAN DIEGO, July 1, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference
SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatment...
Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021
Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?
Heron Therapeutics Announces $150 Million Convertible Debt Financing
SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissory notes (the "Notes") in ...